Olga Giouleme

Prof. Olga Giouleme


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DKDimitrios Kouroupis
Dimitrios Kouroupis
IZIoanna Zografou
Ioanna Zografou
PDPanagiotis Doukelis
Panagiotis Doukelis
DPDimitrios Patoulias
Dimitrios Patoulias
Djordje PopovicDjordje Popovic
Djordje Popovic
TKTheocharis Koufakis
Theocharis Koufakis
Background/Objectives: Systemic and tissue inflammation play a crucial role in the pathophysiology of cardiometabolic disorders. Presepsin is a newly discovered marker of acute phase inflammation that is produced by monocytes or macrophages in response to bacterial infection and is a soluble fraction of the lipopolysaccharide (LPS) receptor. LPS is an endotoxin that, through the breakdown of the intestinal barrier, penetrates the systemic circulation and is an important bacterial mediator in the pathogenesis of sepsis and septic shock. Methods: A narrative review of the existing literature. Results: A growing body of evidence demonstrates that intestinal dysbiosis is involved in the pathogenesis of diabetes mellitus (DM) and cardiovascular (CV) disease, leading to increased circulating LPS concentrations in people with cardiometabolic disorders, even in the absence of infection. These data provide the theoretical background for a link between presepsin, DM, and CV pathology. Preliminary studies suggest that presepsin levels are downregulated in patients with well-controlled type 2 DM and correlate with continuous glucose monitoring metrics in infection-free individuals with type 1 DM. However, prospective data on the association between presepsin and the risk of diabetic complications are currently lacking. Presepsin has also been found to be elevated in infection-free individuals with myocardial infarction, heart failure, and myocarditis compared to controls and has been shown to correlate with mortality risk in subjects at high CV risk. Conclusions: The clinical utility of presepsin in the monitoring of patients with cardiometabolic disorders warrants further investigation by future studies.

4 June 2025 in Current Obesity Reports
Verified
Journal Article
Open access
PDF file
IFIoanna Filimidou
Ioanna Filimidou
MOMyrsini Orfanidou
Myrsini Orfanidou
AGAntonis Goulas
Antonis Goulas
OGOlga Giouleme
Olga Giouleme
SPStergios A Polyzos
Stergios A Polyzos
Background: The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is multifactorial. Fibroblast growth factor-21 (FGF-21) has been proposed to be associated with NAFLD, but data on its circulating levels in patients with NAFLD are to date conflicting. Aims: The synthesis and comparison of data on circulating FGF-21 between patients with NAFLD and controls without NAFLD. Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library and Scopus, complemented by hand-searching. Forty-four observational studies with overall 15,563 participants (9548 controls and 6015 NAFLD patients) were included in the study. Results: Circulating FGF-21 was higher in patients with NAFLD compared to controls (standardized mean difference [SMD]: 0.61; 95% confidence interval [CI]: 0.44, 0.77; p < 0.00001). Subgroup analysis showed higher FGF-21 levels in patients with nonalcoholic steatohepatitis (NASH) compared to controls (SMD: 1.30; 95% CI: 0.35, 2.24; p = 0.007), but not between hepatic steatosis and controls, or hepatic steatosis and NASH. Furthermore, the findings were more robust in the subgroup of studies with NASH-related cirrhosis than those without them (p = 0.0004). Sensitivity analysis further supported the findings. Heterogeneity was high in all comparisons. Meta-regression analyses showed that FGF-21 SMD between NAFLD patients and controls was positively associated with the rate of patients with type 2 diabetes mellitus per study, and this could explain 49.2% of the heterogeneity among studies. Conclusions: Circulating FGF-21 levels were higher in NAFLD patients than controls, which may be possibly attributed to those with advanced disease (NASH and related cirrhosis). Lay summary: Circulating fibroblast growth factor-21 levels were higher in patients with nonalcoholic fatty liver disease compared to controls. This is primarily attributed to the higher levels observed in patients with advanced disease (steatohepatitis and related cirrhosis).

21 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKANASTASIA KATSOULA
ANASTASIA KATSOULA
GAGeorgios Axiaris
Georgios Axiaris
AMAfroditi Mpitouli
Afroditi Mpitouli
MPMaria Palatianou
Maria Palatianou
ACANGELIKI CHRISTIDOU
ANGELIKI CHRISTIDOU
OGOlga Giouleme
Olga Giouleme
Background: The Inflammatory Bowel Disease-Disk (IBD-Disk) is a physician-administered tool that evaluates the functional status of patients with Inflammatory Bowel Disease (IBD). The aim of our study was to validate the content of the IBD-Disk in a Greek cohort of IBD patients. Methods: Two questionnaires [the IBD Disk and the IBD-Disability Index (IBD-DI)] were translated into Greek and administered to IBD patients at baseline visit, after 4 weeks and 6 months. Validation of the IBD Disk included measuring of concurrent validity, reproducibility, and internal consistency. Results: A total of 300 patients were included at baseline and 269 at follow-up. There was a good correlation between the total scores of the IBD-Disk and IBD-DI at baseline (Pearson correlation 0.87, p < 0.001). Reproducibility of the total IBD-Disk score was very good [intra-class correlation coefficient (ICC), 95% confidence interval (CI) 0.89 (0.86–0.91)]. Cronbach’s coefficient alpha for all items achieved 0.90 (95%CI 0.88–0.92), demonstrating a very good homogeneity of the IBD-Disk items. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Conclusions: The Greek version of the IBD-Disk proved to be a reliable and valid tool in detecting and assessing IBD-related disability in a Greek cohort of IBD patients.

Verified
Journal Article
Open access
PDF file
TKTheocharis Koufakis
Theocharis Koufakis
DKDimitrios Kouroupis
Dimitrios Kouroupis
Areti KourtiAreti Kourti
Areti Kourti
KKKaralazou Karalazou
Karalazou Karalazou
KTKaterina Thisiadou
Katerina Thisiadou
Kali MakedouKali Makedou
Kali Makedou
Objective: Obesity is characterized by chronic inflammation and gut dysbiosis, yet circulating markers reflecting intestinal immune activation remain limited. Regenerating islet-derived protein 3 alpha (REG3α), an antimicrobial peptide secreted by intestinal Paneth cells, plays a pivotal role in mucosal defense and mirrors microbial–epithelial interactions. In this cross-sectional study, we aimed to examine circulating REG3α levels in infection-free adults with obesity, overweight, and normal weight, and to explore their associations with vitamin D supplementation and biomarkers of inflammation and dysbiosis. Methods: Sixty-nine participants were stratified into control, overweight, and obesity groups. Serum REG3α, interleukin-6 (IL-6), β-defensin-2, high-sensitivity c-reactive protein, ferritin, and presepsin were assessed. Vitamin D status and supplementation history were recorded. Multivariable linear regression, principal component analysis (PCA), and bootstrap mediation models were applied to explore associations and potential indirect effects. Results: REG3α concentrations were higher in overweight and obesity compared to controls (646 ± 217 vs. 521 ± 311 ng/mL); however, the difference was not significant (p = 0.15). Vitamin D supplementation was inversely associated with REG3α (p = 0.06), and this effect appeared weaker in obesity. REG3α correlated positively with IL-6 (ρ = 0.28) and β-defensin-2 (ρ = 0.43). PCA revealed a shared inflammatory–mucosal activation component that predicted REG3α levels. Exploratory mediation suggested a partial indirect effect of vitamin D via reduced inflammatory activity. Conclusions: Circulating REG3α shows associations with indicators of inflammation and vitamin D supplementation in individuals with overweight and obesity. Although differences between groups did not reach statistical significance, the observed trends suggest possible links between mucosal immune activity and metabolic status. These exploratory results warrant validation in larger, longitudinal studies before any biomarker role can be established.

15 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Christos MademlisChristos Mademlis
Christos Mademlis
AKAnastasia Katsoula
Anastasia Katsoula
TKTheocharis Koufakis
Theocharis Koufakis
PPPaschalis Paschos
Paschalis Paschos
AKAristeidis Kefas
Aristeidis Kefas
OGOlga Giouleme
Olga Giouleme
Background and Aim: The therapeutic landscape for ulcerative colitis (UC) is rapidly evolving, with an increasing number of biologic agents available. This systematic review and meta-analysis synthesized randomized controlled trials (RCTs) data on biologic therapies for achieving key endoscopic and histologic endpoints in moderate to severe UC. Methods: A systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science and grey literature was conducted through November 2024. Separate meta-analyses were performed for induction and maintenance. A random-effects model was used to estimate relative risks (RR), with 95% confidence intervals (CI), and confidence in estimates was evaluated with the GRADE approach (Grading of Recommendation Assessment, Development and Evaluation). Results: We included 40 RCTs (13 therapies, 14,369 patients). Thirty-two trials provided data in induction and twenty-eight in maintenance. During induction, all biologic therapies, except mirikizumab and filgotinib 100 mg, demonstrated superiority over placebo (RR 2.02, 95% CI: 1.76–2.31, I2 = 72%) for endoscopic improvement. Upadacitinib showed the highest efficacy (RR 5.53, 95% CI: 3.78–8.09). For mucosal healing, all interventions were superior to placebo (RR 2.95, 95% CI: 2.11–4.13, I2 = 61%), except filgotinib 100 mg. Risankizumab showed the highest efficacy (RR 10.25, 95% CI: 2.49–42.11). In maintenance, all therapies showed superiority over placebo for endoscopic improvement. For mucosal healing all therapies were superior to placebo, except risankizumab. Upadacitinib 30 mg showed the highest efficacy (RR 4.01, 95% CI: 1.81–8.87). Conclusions: Biologic and small-molecule therapies demonstrated substantial efficacy in achieving key endpoints. Standardized outcome definitions and further head-to-head RCTs are essential to strengthen confidence in our findings.

29 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAlexandra Eleftheria Menni
Alexandra Eleftheria Menni
GTGeorgios Tzikos
Georgios Tzikos
PGPatroklos Goulas
Patroklos Goulas
GCGeorge Chatziantoniou
George Chatziantoniou
AVAngeliki Vouchara
Angeliki Vouchara
SASTYLIANOS APOSTOLIDIS
STYLIANOS APOSTOLIDIS
Background/Objectives: The potential side effects of the use of biological agents in the perioperative period are still under investigation. This animal prospective study aimed to evaluate the overall impact of biological factor administration after intestinal surgery. Methods: This study included 80 female Wistar rats sorted into four groups: three groups received one of the biological factors, infliximab, vedolizumab, or ustekinumab; the control group received placebo therapy. After enterotomy and intestinal anastomosis, the bursting pressure (BP) of the anastomosis was compared among the groups on postoperative days (PODs) 3 and 7. Results: On POD3, the control group presented with a significantly higher mean BP (154.6 ± 39.7 mmHg) compared to the infliximab (66.8 ± 10.4 mmHg), vedolizumab (105.4 ± 37.6 mmHg), and ustekinumab (98.8 ± 47.9 mmHg) groups. A post hoc analysis among the three biological agent groups revealed differences only when comparing infliximab and vedolizumab rats with the controls on POD3 (p < 0.001) and with the ustekinumab rats on POD7, having a greater mean BP (282.5 ± 80.1 mmHg, p = 0.031). No differences were observed regarding the event of broken anastomosis among the four groups. Conclusions: This experimental study’s findings highlight the varying detrimental effects of different biological agents on the strength of intestinal anastomosis, with ustekinumab demonstrating superior performance.